Thus, we again indirectly confirmed that PU.1 is a very important barrier to AML pathogenesis and that hypermethylation of its promoter is abrogated by AZA therapy, which may play a key role in its targeting effects. This evidence concerns the gene SPI1 and acute myeloid leukemia.